• Dialogues in Diabetes
  • CME

  • Dialogues in Diabetes

  • Author(s)/Faculty: Silvio E. Inzucchi, MD; Cyrus V. Desouza, MBBS; Vivian A. Fonseca, MD; Julio Rosenstock, MD; George L. Bakris, MD, FAHA, FASN
    Source: Endocrine Today
    Type: Journal Articles/Items: 7
    Release Date: 12/1/2011 Expiration Date: 12/31/2012
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education

  • Although new medications and combination regimens have been shown to improve glycemic control, current clinical management approaches have failed to achieve the glycemic levels most likely to provide optimal health outcomes for patients with type 2 diabetes. As the disease progresses, many patients will require additional interventions to maintain glycemic control. The challenge for clinicians is to understand how these new agents work and when they should be integrated into the current treatment paradigm for diabetes. This activity focuses on these emerging therapeutics, allowing physicians to increase their knowledge on the rationale, efficacy, safety and implementation of updated treatment algorithms.

Sponsorship Statement:
This continuing medical education activity is sponsored by

Support Statement: This activity is supported by an educational grant from

Target Audience:
The intended audience for this activity is endocrinologists, internal medicine physicians, family practice physicians, diabetologists, certified diabetes educators, and other healthcare professionals involved in the treatment of patients with Type 2 diabetes.

Learning Objectives:
At the conclusion of this activity participants should be able to:

  • Characterize emerging therapies for diabetes in terms of their mechanism of action, physiological basis, and importance in achieving glycemic goals and improving patient care.
  • Select treatment regimens that will best enable patients with T2DM to achieve guideline-recommended targets for glycemic, lipid, and blood pressure control, cardiometabolic risk reduction, and improvement of outcomes.
  • Identify opportunities to improve medication adherence among patients with T2DM.

Chief Medical Editor:
Vivian A. Fonseca, MD
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Contributing Faculty:
George L. Bakris, MD, FAHA, FASN
Professor of Medicine
Director, Hypertensive Diseases Center
University of Chicago Pritzker School of Medicine
Chicago, IL

Cyrus V. Desouza, MBBS
Associate Professor, Internal Medicine
Diabetes, Endocrinology and Metabolism
University of Nebraska Medical Center
Omaha, NE

Julio Rosenstock, MD
Director, Dallas Diabetes and Endocrine Center at Medical City
Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Director, Endocrinology
Director, Yale Diabetes Center
Yale University School of Medicine
New Haven, CT

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 1, 2011 to December 31, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 out of 10 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

External Reviewer:
Carol H. Wysham, MD

Medical Writer:
Amanda Justice

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Vivian A. Fonseca, MD
Research Support: Novo Nordisk, Sanofi-Aventis, Eli Lilly, Daiichi-Sankyo, Pamlabs, Reata, Halozyme
Honoraria for Consulting and Lectures: GlaxoSmithKline, Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Daiichi-Sankyo, Pamlabs, Xoma, AstraZeneca

George L. Bakris, MD, FAHA, FASN
 Investigator Initiated Grant/Research Support: Forest Labs, Novartis
National Clinical Trial Principal Investigator Studies: Medtronic, Relapysa
Consulting Fees: Takeda, Abbott, CVRx, Johnson & Johnson, Servier, Eli Lilly, Food and Drug Administration
Speaker Bureaus: Takeda, Novartis
Boards: National Kidney Foundation, American Society of Hypertension

Cyrus V. Desouza, MBBS
 Consulting Fees: Takeda, Novo Nordisk

Julio Rosenstock, MD
Scientific Advisory Boards/Honorarium/Consulting Fees: Pfizer, Roche, Sanofi, Novo Nordisk, Eli Lilly, MannKind, GlaxoSmithKline, Takeda, Daiichi Sankyo, Johnson & Johnson, Novartis, Boehringer Ingelheim and Lexicon
Grants/Research Suppor: Merck, Pfizer, Sanofi, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, Lexicon and Boehringer Ingelheim

Silvio E. Inzucchi, MD
Consulting Fees: Merck, Takeda, Boehringer Ingelheim
Contracted Research: Eli Lilly
Lecture Fees: Novo Nordisk
Study Drug: Provided by Takeda for NINDS study

External Reviewer reports the following relationship(s):
Carol H. Wysham, MD
Consulting Fees: Amylin Pharmaceuticals, Boehringer Ingelheim, Johnson & Johnson, Sanofi-Aventis
Fees for Non-CME Services: Amylin Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi-Aventis

Medical Writer reports the following relationship(s):
Amanda Justice
No relevant financial relationships to disclose

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Vindico Medical Education Editorial Staff:
Chief Medical Officer
William C. Lloyd, III, MD, FACS

Medical Director
Ronald Codario, MD, FACP

Director of Medical Education
Chris Rosenberg

Managing Editor
Jill Rollet

Program Manager
Darla Thompson

Publication Design
Kimi Dolan